

**TANKE BIOSCIENCES CORP**

**321 W. Winnie Lane #104**  
**Carson City, NV 89703, USA**

**929-320-5655**

**Quarterly Report**

**For the Period Ending: June 30, 2025**

**Outstanding Shares**

The number of shares outstanding of our Common Stock was:

25,464,279 as of June 30, 2025 *(Current Reporting Period Date or More Recent Date)*

25,464,279 as of December 31, 2024 *(Most Recent Completed Fiscal Year End)*

**Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes:  No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

**Change in Control**

Indicate by check mark whether a Change in Control<sup>14</sup> of the company has occurred during this reporting period:

Yes:  No:

---

<sup>14</sup> "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities.

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets.

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Tanke Biosciences Corp – effective February 2011

f./k./a. Greyhound Commissary Inc

Current State and Date of Incorporation or Registration: Nevada, October 2007

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

None

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None.

Address of the issuer's principal executive office:

Tanke Biosciences Corp.  
321 W. Winnie Lane #104, Carson City, NV 89703, USA

Address of the issuer's principal place of business:

Check if the principal executive office and principal place of business are the same address:

5645 Coral Ridge Dr Suite #153, Coral Springs, FL 33067

The address of the Best Energy Management, LLC subsidiary:  
5645 Coral Ridge Dr Suite #153, Coral Springs, FL 33067

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:  Yes:  If Yes, provide additional details below:

On January 20, 2021, the District Court of Clark County, Nevada, case number A20-826434-C, entered an Order Granting Application for Appointment (the "Order") of SSM Monopoly Corporation as Custodian of the Company. Pursuant to the Order, SSM Monopoly Corporation (the "Custodian") has the authority to take any actions on behalf of the Company, which are reasonable, prudent or for the benefit of the Company, including, but not limited to, issuing shares of stock and issuing new classes of stock, as well as entering into contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter. On December 7, 2021, the Custodian filed a Supplement to the Motion to discharge Custodianship and enter final order. In this Supplement, the Custodian petitioned the court to (i) approve the acts taken by the Custodian, including the appointment of management, cancellation of 9,011,469 shares and the conducting of a shareholder meeting, (ii) discharge SSM Monopoly as Custodian of the Company and (iii) returning control to the Board of Directors. On January 6, 2022, the District Court of Clark County, Nevada approved the Order of Final Discharge

On October 6, 2021, in a private transaction, the Custodian entered into a Securities Purchase Agreement (the "SPA") with EROP Enterprises LLC, a company located in Georgia, to sell the 2021 Series A Preferred. Upon closing of the SPA on October 6, 2001, EROP Enterprises LLC acquired 60% voting control of the Company.

## 2) Security Information

### Transfer Agent

Name: Pacific Stock Transfer  
Phone: 702-361-3033  
Email: luke@pacificstocktransfer.com  
Address: 6725 Via Austin Pkwy., Ste 300 Las Vegas, NV 89119

### Publicly Quoted or Traded Securities:

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	TNBI	
Exact title and class of securities outstanding:	Common	
CUSIP:	87583Y107	
Par or stated value:	\$0.001	
Total shares authorized:	300,000,000	as of date: June 30, 2025
Total shares outstanding:	25,464,279	as of date: June 30, 2025
Total number of shareholders of record:	173	as of date: June 30, 2025

### Other classes of authorized or outstanding equity securities that do not have a trading symbol:

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of securities outstanding:	Special 2021 Series A Preferred Stock	
CUSIP:	N/A	
Par or stated value:	\$0.001	
Total shares authorized:	1	as of date: June 30, 2025
Total shares outstanding:	0	as of date: June 30, 2025
Total number of shareholders of record:	0	as of date: June 30, 2025
Exact title and class of securities outstanding:	Special 2021 Series B Preferred Stock	
CUSIP:	N/A	
Par or stated value:	\$0.001	
Total shares authorized:	1,000	as of date: June 30, 2025
Total shares outstanding:	300	as of date: June 30, 2025
Total number of shareholders of record:	5	as of date: June 30, 2025

### Security Description:

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

#### 1. For common equity, describe any dividend, voting and preemption rights.

Holders of our common stock have one voting right for each common stock owned and do not have any rights to dividends and do not have any preemptive rights.

#### 2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Holders of our 2021 Series B Preferred Stock have 60% voting rights over all classes of our stock and each share of our 2021 Series B Preferred Stock is convertible into 50,000 shares of our common stock. As noted elsewhere, there are currently 300 shares of our 2021 Series B Preferred Stock outstanding which are currently convertible into 15,000,000 shares of our common stock. We have the right to issue an additional 700 shares of our 2021 Series B Preferred Stock in the future. If all of these 700

shares of our 2021 Series B Preferred Stock were issued, they would be convertible into an additional 35,000,000 shares of our common stock.

3. Describe any other material rights of common or preferred stockholders.

N/A

4. Describe any material modifications to the rights of holders of the company's securities that have occurred over the reporting period covered by this report.

N/A

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No:  Yes:  (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: 1/1/2023									
Opening Balance									
Common: 20,612,614									
Preferred: 1									
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time Of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
3/24/2023	New Issuance	500,000	Common stock	\$0.015	No	Kalimah Unipessol LDA (Anthony Demetroulakos)	Acquisition	Restricted	Exempt
1/12/2024	New Issuance	66,666	Common stock	\$0.075	No	Angela Kay	Stock Purchase	Restricted	Exempt
1/12/2024	New Issuance	133,333	Common stock	\$0.075	No	Michael Mussebeau	Stock Purchase	Restricted	Exempt
1/18/2024	New Issuance	26,666	Common stock	\$0.075	No	Adam Ernest	Stock Purchase	Restricted	Exempt
1/22/2024	New Issuance	500,000	Common stock	\$0.01	No	Trinity Sponsor Group LLC (Hortencia Torres)	Stock Purchase	Restricted	Exempt
7/1/24	New Issuance	650,000	Common stock	\$0.01	No	Learner Labs LLC - Alex Rowland	Stock Purchase	Restricted	Exempt
7/1/24	New Issuance	650,000	Common stock	\$0.01	No	Sareesi Holdings LLC Ziad Zaideh	Stock Purchase	Restricted	Exempt
7/1/24	New Issuance	650,000	Common stock	\$0.01	No	Footprint Strategy Holdings LLC Ness Zaideh	Stock Purchase	Restricted	Exempt
5/7/24	New Issuance	100,000	Common stock	\$0.10	No	Win Capital Mihir Shaha	Stock Purchase	Restricted	Exempt

11/8/24	New Issuance	125,000	Common stock	\$0.01	No	Thomas Ford	Stock Purchase	Restricted	Exempt
11/8/24	New Issuance	125,000	Common stock	\$0.01	No	Brian West	Stock Purchase	Restricted	Exempt
12/23/24	New Issuance	125,000	Common stock	\$0.01	No	Tom Stein	Board Services	Restricted	Exempt
12/23/24	New Issuance	125,000	Common stock	\$0.01	No	Hortencia Torres	Board Services	Restricted	Exempt
12/23/24	New Issuance	125,000	Common stock	\$0.01	No	Ken Marks	Board Services	Restricted	Exempt

<p>Shares outstanding on Date of This Report: Ending Balance Date 6/30/2025 Common: 25,464, 279 Special 2021 Series A Preferred : 0 Special 2021 Series B Preferred : 300</p>	
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

**Example:** A company with a fiscal year end of December 31<sup>st</sup>, 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

## B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance \$(include accrued interest)	Maturity Date	Conversion Terms	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion <sup>25</sup>	Name of Noteholder	Reason for Issuance (e.g., Loan, Services, etc.)
<u>12/2/2021</u>	<u>\$20,000</u>	25,200	<u>12/31/2023</u>	<u>The Note and all accrued interest convert at \$0.05</u>	0	496,000	<u>West Orange Capital (Brian West)</u>	<u>Loan</u>
<u>12/28/2021</u>	<u>\$25,000</u>	31,500	<u>12/31/2023</u>	<u>The Note and all accrued interest convert at \$0.05</u>	0	540,000	<u>West Orange Capital (Brian West)</u>	<u>Loan</u>
<u>8/9/2022</u>	<u>\$20,000</u>	23,600	<u>12/31/2023</u>	<u>The Note and all accrued interest convert at \$0.05</u>	0	432,000	<u>West Orange Capital (Brian West)</u>	<u>Loan</u>
<u>12/21/2022</u>	<u>\$5,000</u>	5,900	<u>12/21/2023</u>	<u>The Note and all accrued interest convert at \$0.05</u>	0	108,000	<u>West Orange Capital (Brian West)</u>	<u>Loan</u>
<u>2/13/2023</u>	<u>\$10,000</u>	11,000	<u>2/13/2024</u>	<u>The Note and all accrued interest convert at \$0.05</u>	0	216,000	<u>West Orange Capital (Brian West)</u>	<u>Loan</u>

<sup>25</sup> The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

<u>3/21/2023</u>	<u>\$10,000</u>	10,625	<u>3/21/2024</u>	<u>The Note and all accrued interest convert at \$0.05</u>	0	210,000	<u>West Orange Capital (Brian West)</u>	<u>Loan</u>
<u>3/30/2023</u>	<u>\$10,000</u>	10,625	<u>3/30/2024</u>	<u>The Note and all accrued interest convert at \$0.05</u>	0	210,000	<u>West Orange Capital (Brian West)</u>	<u>Loan</u>
<u>6/14/2023</u>	<u>\$25,000</u>	27,500	<u>6/14/2024</u>	<u>The Note and all accrued interest convert at \$0.05</u>	0	540,000	<u>West Orange Capital (Brian West)</u>	<u>Loan</u>
<u>12/20/23</u>	<u>15,000</u>	16,500	<u>12/20/2024</u>	<u>The Note and all accrued interest convert at \$0.05</u>	0	324,000	<u>West Orange Capital (Brian West)</u>	<u>Loan</u>

**Total Outstanding Balance:** \$165,100

**Total Shares:** 3,302,000.00

Any additional material details, including footnotes to the table are below:

On December 17, 2024, West Orange Capital acquired all outstanding convertible notes from EROP Enterprises, LLC

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on [www.OTCMarkets.com](http://www.OTCMarkets.com).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Tanke Biosciences Corp (OTC: TNBI) is a diversified company focused on identifying emerging, growth stage businesses, which have achieved verifiable market validation, proof of concept, and/or customer adoption of their platform solution(s) as evidenced by sustainable, recurring revenue traction; in order to provide them with the experienced operational resources/support and capital infusion in order to scale operations to drive managed, profitable growth and drive shareholder value in their respective market areas.

The current business operations is an change in direction for Tanke Biosciences, which was previously limited to energy monitoring business, based upon as part of an initiative to redefine the Company's core strategic direction, and then build the core products, services, tools, systems and infrastructure in support of that new company mission statement. The initiative was driven by the Brand Craft Holdings team which delivered their recommendations for a revised business strategy and approach which was approved by both the Tanke Biosciences management and Board in the fourth quarter of 2024, for implementation in 2025, which will include exiting the energy monitoring business.

The recommendations entailed pivoting the Company into a diversified company structure focused on participating in early stage companies that are leading edge in their respective, addressable markets. As such, the management, Brand Craft Holdings and the Board of the Company are implementing a structure which enables identifying and supporting entities that are leading edge in their respective market niches, and that have expectations of enhancing shareholder values through scalable and sustainable revenue growth and enhanced profitability. Our support will include both organizational expertise and capital infusion, focused on the design, implementation and execution of scalable, efficient and effective operating infrastructures with swift going to market motions to drive revenue and profits. In addition, it included divesting the current energy monitoring operations, as that was no longer a fit or focus for the company.

The Brand Craft Holdings team initiated the implementation of the new strategy and approach in Q1 2025, initially identifying the management team with industry, functional and regulatory experts who will begin identifying target portfolio companies..

To drive the implementation of our strategy, in Q1 2025, TNBI engaged Vincent Renz as its new Chief Executive Officer and appointed him to our Board of Directors. Mr. Renz brings over 30 years of leadership experience at C-Suite level, having served as CTO of eResearch Technology, CEO/COO of NewCardio, Inc, COO of Clinphone, Sr. Vice President, Client Services of Computron Software. Mr. Renz has served most recently as the President and Founder of Straight4ward Advisory Services – a boutique professional services company. He is experienced with driving significant value creation for shareholders and delivering on both turnaround and growth strategies.

Additionally in Q1 2025, TNBI appointed John Hopkins as Executive Chairman of our Board of Directors. Mr. Hopkins brings a wealth of executive leadership experience across finance, strategic planning, and corporate transformation. He began his career as an audit

manager at Coopers & Lybrand (now PwC) before transitioning to Arco Chemical Company, where he played a key role in re-engineering the organization through various controller, planning, and treasury positions until its acquisition. He then served as Vice President, Controller, and Head of Finance at Cambrex Corp, a life sciences company based in New Jersey. Mr. Hopkins's first CFO appointment was at Measurement Specialties, a leading designer of sensors and sensor-based consumer products. Joining during a critical SEC investigation, he successfully led the financial restructuring efforts, returning the company to profitability.

Further, an initial management advisory team, which will deliver extensive leadership, managerial, operational and technical experience across multiple industries (i.e. healthcare, life sciences, government, financial services, enterprise software, manufacturing, distribution, consumer products, medical devices, consulting services, etc.) and functional areas (i.e. sales, marketing, customer success, program management, product development/management, information technology, quality/regulatory systems, partnerships, channel management, etc.), has been identified and engaged. With these additions, the combination of TNBI's current management, Board of Directors and Brand Craft team bring decades of proven leadership expertise across multiple industry verticals and have successfully driven tangible growth in organizations with a relentless focus on operational excellence.

The advisory team also initiated their due diligence review and analysis of the potential opportunities, which included three SaaS technology platforms; a mobile first employee engagement and development platform focused on an underserved market - front line workers, an AI enabled platform which supports the hiring of veterans and their families to best leverage the skills and experiences gained while serving in the military, and a healthcare wearable solution to support remote/virtual care and monitoring for at risk pregnancies. At this time, we are actively engaged in discussions for defining potential operational support and capital infusion to drive their next stage of revenue and profitability growth. If and when we enter binding letters of intent or definitive agreements with any of these potential opportunities, we will publicly announce those milestones.

To summarize our business strategy and approach, TNBI as a diversified company committed to identifying and investing in companies, in strategic and complementary vertical industries, with business models that have achieved "proof of concept" with their technology platforms and revenue streams. Our team of seasoned-operating managers will partner with the existing management to deliver cost efficient, high quality and scalable operations.

B. List any subsidiaries, parent company, or affiliated companies.

Best Energy Monitoring, LLC

C. Describe the issuers' principal products or services.

Please see Section 4.A. above regarding the issuer's business operations for a discussion of the issuer's principal products and services.

## 5) Issuer's Facilities

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Issuer utilizes space provided at no cost located in Coral Springs, FL.

## 6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all the officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

*The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.*

<b>Individual Name</b> (First, Last) or <b>Entity Name</b> (Include names of control person(s) if a corporate entity)	<b>Position/Company</b> <b>Affiliation</b> (ex: CEO, 5% Control person)	<b>City and State</b> (Include Country if outside U.S.)	<b>Number of</b> <b>Shares Owned</b> (List common, preferred, warrants and options separately)	<b>Class of</b> <b>Shares</b> <b>Owned</b>	<b>Percentage of</b> <b>Class of Shares</b> <b>Owned</b> (undiluted)
Tom Stein	COO, Board Member	Boca Raton, FL	500,000	Common	1.7%
Ken Marks	Board Member	New York, NY	500,000	Common	1.7%
Hortencia Torres	Board Member	Washington DC	1,000,000	Common	3.4%
Aquamen, LLC Dan Boutcher	5% Owner	New York, New York	79	2021 Series B Preferred	26.33%
BrandCraft Holdings LLC Tom Stein, Dan Boutcher	5% Owner	Delray Beach FL	173	2021 Series B Preferred	57.66%
BrandCraft Holdings LLC Tom Stein, Dan Boutcher	5% Owner	Delray Beach, FL	4,100,000	Common	15.4%
Vincent Renz	CEO, Board Member	Princeton, NJ	48	2021 Series B Preferred	16.00%
John Hopkins	Chairman of the Board	Philadelphia	40	2021 Series B Preferred	13.3%

Confirm that the information on this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, log in to [www.OTCIQ.com](http://www.OTCIQ.com) to update your company profile.

## 7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations).

No

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

No

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such a person's involvement in any type of business or securities activities.

No

6. Been the subject of a U.S. Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

### 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed. Confirm that the information on this table matches your public company profile on [www.OTCMarkets.com](http://www.OTCMarkets.com). If any updates are needed to your public company profile, update your company profile.

#### Securities Counsel

Name: Jeffrey M. Quick  
Firm: Quick Law Group PC  
Address 1: 1035 Pearl St, Suite 403  
Address 2: Boulder, Colorado 80302  
Phone: (720) 259-3393  
Email: jquick@quicklawgroup.com

#### Accountant or Auditor

None

Name:  
Firm:  
Address 1:  
Address 2:  
Phone:  
Email:

#### Investor Relations

None

Name:  
Firm:  
Address 1:  
Address 2:  
Phone:  
Email:

*All other means of Investor Communication:*

None

X (Twitter):  
Discord:  
LinkedIn  
Facebook:  
[Other ]

#### Other Service Providers

Provide the name of any other service provider that **assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

None

Name:  
Firm:  
Nature of Services:  
Address 1:  
Address 2:  
Phone:  
Email:

**9) Disclosure & Financial Information**

A. This Disclosure Statement was prepared by (name of individual):

Name: **Tom Stein**  
Title: **COO**  
Relationship with the Issuer: **Consultant**

B. The following financial statements were prepared in accordance with:

- IFRS  
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: **Vincent Renz**  
Title: **CEO**  
Relationship with the Issuer: **Consultant**

Describe the qualifications of the person or persons who prepared the financial statements: **20 years of accounting experience.**

Provide the following qualifying financial statements:

- Audit letter, if audited.
- Balance Sheet.
- Statement of Income.
- Statement of Cash Flows.
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Tanke Biosciences Corporation's June 30, 2025 and 2024 Year End Financial Statements are attached hereto at the end of this section.

**Financial Statement Requirements:**

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

**TANKE BIOSCIENCES CORP.  
INDEX TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS**

Unaudited Consolidated Balance Sheets as of March 31, 2025 and March 31, 2024 12

Unaudited Consolidated Profit & Loss Statements for the Year Ended March 31, 2025 and 2024 14 Unaudited  
Consolidated Statements of Stockholders' Deficit for Year Ended March 31, 2024 and 2023 15 Unaudited  
Consolidated Statements of Cash Flows for the Year Ended March 31, 2024 and 2023 16



# Balance Sheet

## Tanke Biosciences

As of June 30, 2025

DISTRIBUTION ACCOUNT	TOTAL	
	AS OF JUNE 30, 2025	AS OF DECEMBER 31, 2024 (CUSTOM)
<b>Assets</b>		
Current Assets		
Bank Accounts		
Bank of America 2890		
Tnbi New BOA	37,298	
Wells Fargo		
<b>Total for Bank Accounts</b>	<b>\$37,298</b>	<b>0</b>
Accounts Receivable		
Accounts receivable (A/R)		
<b>Total for Accounts Receivable</b>	<b>0</b>	<b>0</b>
Other Current Assets		
<b>Total for Current Assets</b>	<b>\$37,298</b>	<b>0</b>
Fixed Assets		
Tools, machinery, and equipment		
Tools, machinery, and equipment	\$51,000.00	\$51,000.00
Accumulated depreciation	-10,651	-9,478
<b>Total for Tools, machinery, and equipment</b>	<b>\$40,349</b>	<b>\$41,522</b>
<b>Total for Fixed Assets</b>	<b>\$40,349</b>	<b>\$41,522</b>
Other Assets		
Goodwill	24,000	24,000
<b>Total for Other Assets</b>	<b>\$24,000</b>	<b>\$24,000</b>
<b>Total for Assets</b>	<b>\$101,648</b>	<b>\$65,522</b>
<b>Liabilities and Equity</b>		
Liabilities		
Current Liabilities		
Accounts Payable		
Accounts Payable (A/P)	226,615	80,064
<b>Total for Accounts Payable</b>	<b>\$226,615</b>	<b>\$80,064</b>
Credit Cards		
Other Current Liabilities		
Debt		
Debt	\$140,000.00	\$140,000.00
Discount on Debt		
Interest Payable	25,100	13,800
<b>Total for Debt</b>	<b>\$165,100</b>	<b>\$153,800</b>
Derivative Liability		
Due to/From Brandcraft		
Due to Related Parties	-1,000	-1,000
Overdraft		
<b>Total for Other Current Liabilities</b>	<b>\$164,100</b>	<b>\$152,800</b>

# Balance Sheet

Tanke Biosciences

As of June 30, 2025

DISTRIBUTION ACCOUNT	TOTAL	
	AS OF JUNE 30, 2025	AS OF DECEMBER 31, 2024 (CUSTOM)
<b>Total for Current Liabilities</b>	<b>\$390,715</b>	<b>\$232,864</b>
Long-term Liabilities		
<b>Total for Liabilities</b>	<b>\$390,715</b>	<b>\$232,864</b>
Equity		
Retained Earnings	-13,241,092	-13,137,160
Net Income	-164,726	-103,932
Additional paid in capital	13,091,286	13,048,286
Common stock	25,464	25,464
Preferred stock		
Preferred Stock B	0	0
<b>Total for Equity</b>	<b>-\$289,068</b>	<b>-\$167,342</b>
<b>Total for Liabilities and Equity</b>	<b>\$101,648</b>	<b>\$65,522</b>

# Profit and Loss

## Tanke Biosciences

April-June, 2025

DISTRIBUTION ACCOUNT	TOTAL	
	APR 1 - JUN 30 2025	JAN 1 - DEC 31 2024 (CUSTOM)
Income		
Services	8,430	
<b>Total for Income</b>	<b>\$8,430</b>	<b>0</b>
Cost of Goods Sold		
<b>Gross Profit</b>	<b>\$8,430</b>	<b>0</b>
Expenses		
Business licenses	1,695	102
General business expenses	0	\$10,851.00
Bank fees & service charges	30	394
Memberships & subscriptions	4,500	9,276
<b>Total for General business expenses</b>	<b>\$4,530</b>	<b>\$20,521</b>
Legal & accounting services	0	0
Legal Fees	6,000	
Accounting fees		3,099
<b>Total for Legal &amp; accounting services</b>	<b>\$6,000</b>	<b>\$3,099</b>
Payroll expenses	0	0
Officers' salaries	-14,000	6,000
<b>Total for Payroll expenses</b>	<b>-\$14,000</b>	<b>\$6,000</b>
Professional Services	67,975	67,790
Tradeshaw	2,500	
Travel	2,338	
Advertising & marketing		1,500
Contract labor		-1,000
Office expenses	0	\$1,345.00
Software & apps		1,092
<b>Total for Office expenses</b>	<b>0</b>	<b>\$2,437</b>
Professional Fees		
Transfer Agent Fees		1,991
<b>Total for Expenses</b>	<b>\$71,038</b>	<b>\$102,440</b>
<b>Net Operating Income</b>	<b>-\$62,608</b>	<b>-\$102,440</b>
Other Income		
Other Expenses		
Depreciation	587	978
Interest Expense	2,650	514
<b>Total for Other Expenses</b>	<b>\$3,237</b>	<b>\$1,492</b>
<b>Net Other Income</b>	<b>-\$3,237</b>	<b>-\$1,492</b>
<b>Net Income</b>	<b>-\$65,844</b>	<b>-\$103,932</b>

**TANKE BIOSCIENCES CORP.**  
**STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT**  
**Through June 30, 2025**  
**(Unaudited)**

	Common Stock		Paid in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Shares	Amount			
Balance, December 31, 2022	20,612,614	\$ 20,613	\$ 12,945,892	\$ -13,054,639	\$ -88,134
Stock issued for acquisition	500,000	500	74,500	—	75,000
Net loss	—	—	—	-39,955	-39,955
Balance, March 31, 2023	21,112,614	21,113	13,020,392	-13,094,594	-53,089
Net loss	—	—	—	-21,432	-21,432
Balance, June 30, 2023	21,112,614	21,113	13,020,392	-13,116,026	-74,521
Net income	—	—	—	9,289	9,289
Balance, September 30, 2023	21,112,614	\$ 21,113	\$ 13,020,392	\$ -13,106,737	\$ -65,232
Net income/(loss)	—	—	—	-30,423	-30,423
Balance, December 31, 2023	21,112,614	\$ 21,113	\$ 13,020,392	\$ -13,137,160	\$ -95,655
Shares Issued	726,665	726			726
Net income/(loss)			\$ 21,274.00	-48,985	-27,711
Balance, March 31 2024	21,839,279	21,839	13,041,666	-13,186,145	-122,640
Net income/(loss)				-1,063	-1,063
Balance, June 30 2024	21,839,279	21,839	13,041,666	-13,187,208	-123,703
Net income/(loss)	450,000	450	4,050	-7,511	-3,011
Balance Sept 30, 2024	22,289,279	22,289	13,045,716	-13,194,719	-126,714
Net income/(loss)	3,175,000	3175	2,570	-46,373	-40,628
Balance December 31, 2024	25,464,279	25,464	13,048,286	-13,241,092	-167,342
Net income/(loss)	-	0	43,000	-98,882	-55,882
Balance March 31, 2025	25,464,279	25,464	13,091,286	-13,339,974	-223,224
Net income/(loss)	-	0	-	-65,844	-65,844
Balance March 31, 2025	25,464,279	25,464	13,091,286	-13,405,818	-289,068

# Statement of Cash Flows

For the 3 months ended June 30, 2025 and 12 months ended December 31,2024

	April - June 2025	Jan - Dec 2024
<b>OPERATING ACTIVITIES</b>		
Net Income	-65,844	-103,932
Adjustments to reconcile Net Income to Net Cash provided by operations:		
Accounts Payable (A/P)	61,738	69,064
Debenture Payable:Interest Payable	2,650	514
Due to Related Parties	0	-1,525
Tools, machinery, and equipment:Accumulated depreciation	587	978
Total Adjustments to reconcile Net Income to Net Cash provided by operations:	<b>64,975</b>	<b>69,031</b>
Net cash provided by operating activities	<b>-869</b>	<b>-34,901</b>
INVESTING ACTIVITIES	0	0
FINANCING ACTIVITIES	0	0
Additional paid in capital	0	27,893
Common stock	0	4,352
Net cash provided by financing activities	<b>0</b>	<b>32,245</b>
Net cash increase for period	<b>-869</b>	<b>-2,656</b>
Cash at beginning of period	<b>38,168</b>	<b>2,656</b>
Cash at end of period	<b>37,299</b>	<b>0</b>

Sunday, Mar 30, 2025 01:29:11 PM GMT-7

**TANKE BIOSCIENCES CORP.**  
**NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025 AND 2024**

**NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS**

Tanke Bioscience Corp. (the “Company”, “TNBI” “we”, “us” or “our”), a Nevada corporation, has a fiscal year end of December 31st and is listed on the OTC Pink Markets under the trading symbol TNBI, is a diversified company focused on identifying emerging, growth stage businesses, which have achieved verifiable market validation, proof of concept, and/or customer adoption of their platform solution(s) as evidenced by sustainable, recurring revenue traction; in order to provide them with the experienced operational resources/support and capital infusion in order to scale operations to drive managed, profitable growth and drive shareholder value in their respective market areas.

The current business operations is an change in direction for Tanke Biosciences, which was previously limited to energy monitoring business, based upon as part of an initiative to redefine the Company’s core strategic direction, and then build the core products, services, tools, systems and infrastructure in support of that new company mission statement. The initiative was driven by the Brand Craft Holdings team which delivered their recommendations for a revised business structure and approach which was approved by both the Tanke Biosciences management and Board in the fourth quarter of 2024, for implementation in the first quarter of 2025.

To implement the new business strategy and supporting operations, TNBI brought on a new management team in Q1, including Vincent Renz, as CEO, and John Hopkins, as Executive Chairman. As part of the implementation, the company has identified their initial management advisory team, which will deliver extensive leadership, managerial, operational and technical experience across multiple industries (i.e. healthcare, life sciences, government, financial services, enterprise software, manufacturing, distribution, consumer products, medical devices, consulting services, etc.) and functional areas (i.e. sales, marketing, customer success, program management, product development/management, information technology, quality/regulatory systems, partnerships, channel management, etc.).

In addition, the advisory team also initiated their due diligence review and analysis of the potential investment opportunities, identifying emerging, growth-stage businesses that have achieved verifiable market validation, proof of concept and/or customer adoption along with a path to recurring revenue traction. Our team seeks to provide target businesses improvement in shareholder value with operating efficiency and position them for strategic capital.

As part of this change in business operations, the decision to exit the current energy monitoring business was finalized and approved, to be completed in 2025.

To summarize our business strategy and approach, TNBI as a diversified company committed to identifying and investing in companies, in strategic and complementary vertical industries, with business models that have achieved “proof of concept” with their technology platforms and revenue streams. Our team of seasoned-operating managers will partner with the existing management to deliver cost efficient, high quality and scalable operations.

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Basis of Presentation*

The Company’s unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company as of and for the six month period ended June 30, 2025.

*Use of Estimates*

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

*Cash and Cash Equivalents*

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of June 30, 2025, and June 30, 2024.

### Fair Value of Financial Instruments

The FASB issued ASC 820-10, *Fair Value Measurements and Disclosures*, for financial assets and liabilities. ASC 820-10 provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. ASC 820-10 defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

- Level 1: Quoted prices in active markets for identical assets or liabilities
- Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
- Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

	Fair Value on June 30, 2025	(Level 1)	(Level 2)	(Level 3)
Derivative liabilities	\$ —	\$ —	\$ —	\$ —

	Fair Value on June 30, 2024	(Level 1)	(Level 2)	(Level 3)
Derivative liabilities	\$ -	\$ -	\$ -	\$ -

### Earnings Per Share

Under ASC 260 “Earnings Per Share,” the Company presents basic and diluted earnings (loss) per-share (“EPS”) amounts on the face of the statements of operations. Basic EPS is computed by dividing income (loss) available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. As of June 30, 2025, there are 3,294,000 potentially dilutive shares of common stock from convertible notes payable. Potentially diluted shares are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share.

### **NOTE 3 – GOING CONCERN**

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company has an accumulated deficit of \$13,257,092 as of June 30, 2025. The Company cannot be certain that it will be successful in implementing its strategy and business plan even with the required funding.

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

### **NOTE 4 – ACQUISITION**

On March 24, 2023, the Company acquired Kalimah Unipessol LDA (“Kalimah”), a Portugal Limited Liability Company engaged in energy monitoring for \$5,000 in cash and the issuance of 500,000 shares of its common stock. The Company acquired \$51,000 in equipment and \$24,000 in goodwill.

### **NOTE 5 – CONVERTIBLE NOTE PAYABLE AND DERIVATIVE LIABILITIES**

On December 17, 2024, West Orange Capital acquired the outstanding convertible notes of the Company from EROP Enterprises, LLC. West Orange Capital has agreed to amend the terms of the convertible notes as set forth in the Subsequent Event footnote below.

\$20,000 Convertible Note issued on December 3, 2021 with a conversion price of \$0.05 and a maturity of December 31, 2026.

\$25,000 Convertible Note issued on December 28, 2021 with a conversion price of \$0.05 and a maturity of December 31, 2026.

\$20,000 Convertible Note issued on August 8, 2022 with a conversion price of \$0.05 and a maturity of December 31, 2026.

\$ 5,000 Convertible Note issued on December 21, 2022 with a conversion price of \$0.05 and a maturity of December 31, 2026.

\$10,000 Convertible Note issued on February 13, 2023 with a conversion price of \$0.05 and a maturity of December 31, 2026.

\$10,000 Convertible Note issued on March 21, 2023 with a conversion price of \$0.05 and a maturity of December 31, 2026.

\$10,000 Convertible Note issued on March 30, 2023 with a conversion price of \$0.05 and a maturity of December 31, 2026.

\$25,000 Convertible Note issued on June 14, 2023 with a conversion price of \$0.05 and a maturity of December 31, 2026.

\$15,000 Convertible Note issued on December 20, 2023 with a conversion price of \$0.05 and a maturity of December 31, 2026.

For a summary of our convertible notes, please see the table in Section 3.B. of our OTC Markets Quarterly Report for the period ending June 30, 2025 contained herein.

#### **NOTE 6 – RELATED PARTY TRANSACTIONS**

In January 2024, the Company entered into a services agreement with Tom Stein, our Chief Operating Officer, and BrandCraft Holdings for day-to-day management services for a retainer of \$7,500 and a monthly service fee of \$5,000

#### **NOTE 7 – EQUITY**

##### *Preferred Stock*

On January 20, 2021, the Company's bankruptcy custodian approved the authorization of one share as preferred stock and designated one share of preferred stock as Special 2021 Series A Preferred Stock at a par value of \$0.001. The 2021 Series A Preferred Stock has 60% voting rights over all our classes of stock and are convertible into 30 million shares of our common stock. As of June 30, 2025, there are no shares of our Special 2021 Series A Preferred Stock outstanding.

On December 19, 2022, the Company authorized 1,000 shares as preferred stock with a par value of \$0.001 and designated 300 shares of preferred stock as Special 2021 Series B Preferred Stock at a par value of \$0.001. The Special 2021 Series B Preferred has 60% voting rights over all classes of stock and is convertible into 50,000 shares of our common stock for each share of Special 2021 Series B Preferred Stock. As of June 30, 2025 and the filing date of this quarterly report, the Company has 300 shares of Special 2021 Series B Preferred Stock outstanding which are convertible into 15,000,000 shares of the Company's common stock.

On December 19, 2022, the Company accepted the offer of EROP Enterprises, the owner of the 1 Share of Special 2021 Preferred Series A, to convert the 1 Share of Special 2021 Series A Preferred Stock into 30,000,000 shares of common stock as outlined in the Special 2021 Series A Preferred Stock Certificate of Designations and to exchange 15,000,000 shares of the common shares for 300 Shares of the newly designated Special 2021 Series B Preferred Stock.

The Company has 300 and 0 shares of its Special 2021 Series B Preferred Stock issued and outstanding as of June 30, 2025 and June 30, 2024, respectively.

##### *Common Stock*

The Company is authorized to issue 300,000,000 shares of \$0.001 par value common stock. The Company has 25,464,279 and 21,112,614 issued and outstanding as of June 30, 2025 and June 30, 2024, respectively.

In January 2024, the Company entered into stock purchase agreements for 226,665 shares.

In January 2024, the Company entered into a stock purchase agreement with Trinity Sponsor Group for 500,000 shares.

In July 2024, the Company received \$4,500 from accredited investors for 450,000 shares.

## **NOTE 8**

In December, 2023, through a series of Stock Purchase Agreements (the "Purchase Agreements"), EROP Enterprises, LLC (the Seller), the majority shareholder of TNBI sold a total of 12,900,000 shares of TNBI's common stock and 300 Shares of Series B Preferred for a total purchase price of \$355,000. There were two purchasers of over 10% of the issued and outstanding shares of TNBI's capital stock following these sales, Brand Craft Holdings, LCC which owns 21.55% of the issued and outstanding shares of TNBI's common stock and 74% of the issued and outstanding shares of the preferred stock and Aquaman LLC which owns 11.36% of the issued and outstanding shares of TNBI's common stock and 26% of the issued and outstanding shares of preferred stock.

## **NOTE 9 - SUBSEQUENT EVENTS**

During the third quarter of 2025, the Company intends to issue to the following individuals the number of shares of the Company's common stock indicated below which were either earned or purchased during the first and second quarter of 2025:

Tom Stein - Chief Operating Officer and Board Member - 250,000 shares for services to the Company

Hortencia Torres - Board Member - 250,000 shares for services to the Company

Ken Marks - Board Member - 250,000 shares for services to the Company

Vincent Renz - Chief Executive Officer and Board Member - 434,265 shares for services to the Company

John Hopkin - Chair Board Member - 434,265 shares for services to the Company

Thomas Hopkins - Shareholder - 1,000,000 shares purchased from the Company at \$0.01 per share

Patrick Hopkins- Shareholder - 1,300,000 shares purchased from the Company at \$0.01 per share

Thomas Dowling II - Shareholder - 800,000 shares purchased from the Company at \$0.01 per share

Aggregate shares of common stock to be issued: 4,718,530. All of these shares will be "restricted securities" as defined by the Securities Act of 1933, as amended.

## Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Vincent Renz, CEO, certify that:

1. I have reviewed this Disclosure Statement for Tanke Biosciences Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 14, 2025 [Date]

/s/Vincent Renz [CEO's Signature]

### *Principal Financial Officer:*

I, Vincent Renz certify that:

1. I have reviewed this Disclosure Statement for Tanke Biosciences Corp.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 14, 2025 [Date]

/s/Vincent Renz [CFO's Signature]